Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.48 |
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3119582 | 0.90 | PDE10A (0.54) | MTORCKS1BSKP1SKP2PDE10A | |
| SCHEMBL27007516 | 0.87 | MTOR (0.47) | MTORCKS1BSKP1SKP2PDE10A | |
| SCHEMBL25986469 | 0.81 | MTOR (0.43) | MTORCKS1BSKP1SKP2PDE10A | |
| SCHEMBL30613801 | 0.80 | P2RY12 (0.42) | — | |
| SCHEMBL25341749 | 0.80 | MTOR (0.50) | MTORCKS1BSKP1SKP2PDE10A | |
| SCHEMBL31016562 | 0.78 | C5AR1 (0.39) | MTORC5AR1PARP1TNKS2PARP2 | |
| SCHEMBL20042662 | 0.78 | C5AR1 (0.39) | MTORC5AR1PARP1TNKS2PARP2 | |
| SCHEMBL1261353 | 0.78 | MTOR (0.49) | MTORCKS1BSKP1SKP2PDE10A | |
| SCHEMBL19357879 | 0.78 | CKS1B (0.48) | MTORCKS1BSKP1SKP2GBA1 | |
| SCHEMBL19358100 | 0.78 | P2RX7 (0.48) | MTORCKS1BSKP1SKP2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516064-B2 | Tetrahydropyridopyrimidines and related analogs for inhibiting YAP/TAZ-TEAD | SpringWorks Therapeutics Inc. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| WO-2023150619-A2 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | MTOR 574/4885CKS1B 299/4885SKP1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.